Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe Notices; Draft Guidance for Industry; Availability, 8297-8298 [2020-02867]

Download as PDF Federal Register / Vol. 85, No. 30 / Thursday, February 13, 2020 / Notices Vascular Atherectomy Devices— Premarket Notification [510(k)] Submissions.’’ It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. III. Electronic Access Persons interested in obtaining a copy of the guidance may do so by downloading an electronic copy from the internet. A search capability for all Center for Devices and Radiological title to identify the guidance you are requesting. IV. Paperwork Reduction Act of 1995 This guidance refers to previously approved collections of information. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3521). The collections of information in the following FDA regulations and guidance have been approved by OMB as listed in the following table: OMB control No. 21 CFR part/section or guidance Topic 807, subpart E .......................................... 812 ............................................................ 820 ............................................................ 807, subparts A through D ....................... 50, 56 ........................................................ 56 .............................................................. 58 .............................................................. 801.150(a)(2) and (e) ............................... ‘‘Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff ’’. Premarket Notification .................................................................................................. Investigational Device Exemption ................................................................................ Current Good Manufacturing Practice (CGMP); Quality System (QS) Regulation ..... Electronic Submission of Medical Device Registration and Listing ............................. Protection of Human Subjects: Informed Consent; Institutional Review Boards ........ Institutional Review Boards .......................................................................................... Good Laboratory Practice (GLP) Regulations for Nonclinical Laboratory Studies ..... Agreement for Shipments of Devices for Sterilization ................................................. Q-submissions .............................................................................................................. 0910–0120 0910–0078 0910–0073 0910–0625 0910–0755 0910–0130 0910–0119 0910–0131 0910–0756 Dated: February 7, 2020. Lowell J. Schiller, Principal Associate Commissioner for Policy. DATES: [FR Doc. 2020–02871 Filed 2–12–20; 8:45 am] Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Electronic Submissions Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Submit electronic comments in the Lane, Rm. 1061, Rockville, MD 20852. following way: • For written/paper comments • Federal eRulemaking Portal: https:// submitted to the Dockets Management www.regulations.gov. Follow the Staff, FDA will post your comment, as instructions for submitting comments. well as any attachments, except for Comments submitted electronically, information submitted, marked and including attachments, to https:// identified, as confidential, if submitted www.regulations.gov will be posted to as detailed in ‘‘Instructions.’’ the docket unchanged. Because your Instructions: All submissions received comment will be made public, you are solely responsible for ensuring that your must include the Docket No. FDA– 2020–D–0064 for ‘‘Pre-Submission comment does not include any Consultation Process for Animal Food confidential information that you or a Additive Petitions or Generally third party may not wish to be posted, Recognized as Safe (GRAS) Notices.’’ such as medical information, your or anyone else’s Social Security number, or Received comments will be placed in confidential business information, such the docket and, except for those submitted as ‘‘Confidential as a manufacturing process. Please note Submissions,’’ publicly viewable at that if you include your name, contact https://www.regulations.gov or at the information, or other information that Dockets Management Staff between 9 identifies you in the body of your a.m. and 4 p.m., Monday through comments, that information will be Friday. posted on https://www.regulations.gov. • Confidential Submissions—To • If you want to submit a comment submit a comment with confidential with confidential information that you information that you do not wish to be do not wish to be made available to the made publicly available, submit your public, submit the comment as a BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2020–D–0064] Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe Notices; Draft Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA, we, or Agency) is announcing the availability of a draft guidance for industry (GFI) #262 entitled ‘‘Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe (GRAS) Notices.’’ This draft guidance document, when finalized, will help industry submit information for effective and efficient consultations with FDA regarding investigational animal food substances. SUMMARY: jbell on DSKJLSW7X2PROD with NOTICES Health guidance documents is available at https://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/ GuidanceDocuments/default.htm. This guidance document is also available at https://www.regulations.gov. Persons unable to download an electronic copy of ‘‘Peripheral Vascular Atherectomy Devices—Premarket Notification [510(k)] Submissions’’ may send an email request to CDRH-Guidance@ fda.hhs.gov to receive an electronic copy of the document. Please use the document number 16013 and complete 8297 VerDate Sep<11>2014 18:34 Feb 12, 2020 Jkt 250001 Submit either electronic or written comments on the draft guidance by April 13, 2020 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. ADDRESSES: You may submit comments on any guidance at any time as follows: PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). E:\FR\FM\13FEN1.SGM 13FEN1 jbell on DSKJLSW7X2PROD with NOTICES 8298 Federal Register / Vol. 85, No. 30 / Thursday, February 13, 2020 / Notices comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https:// www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). Submit written requests for single copies of the guidance to the Policy and Regulations Staff (HFV–6), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send one selfaddressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document. FOR FURTHER INFORMATION CONTACT: Ciro Ruiz-Feria, Center for Veterinary Medicine (HFV–229), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–402–6282, Ciro.Ruiz-Feria@fda.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a draft GFI #262 entitled ‘‘Pre- VerDate Sep<11>2014 18:34 Feb 12, 2020 Jkt 250001 Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe (GRAS) Notices.’’ This draft guidance document, when finalized, will facilitate presubmission consultation between FDA and industry by providing recommendations for submissions to investigational food additive (IFA) files, circumstances under which the submission of study protocols is recommended, information on FDA’s review process for IFA submissions, and best practices for communication between FDA and industry regarding these submissions or related issues. Such consultations are intended to assist industry in complying with applicable requirements if they proceed to filing a food additive petition (animal use) or concluding that a substance is GRAS for its intended use in animal food. Development of this guidance is a requirement of the Animal Drug and Animal Generic Drug User Fee Amendments of 2018 (Pub. L. 115–234). Draft guidance is required to be issued by February 14, 2020, with final guidance issuing not later than 1 year after the close of the comment period on the draft guidance. II. Significance of Guidance This level 1 draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on the pre-submission consultation process for animal food additive petitions or GRAS notices for intended use in animal food. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. III. Paperwork Reduction Act of 1995 This draft guidance refers to previously approved FDA collections of information. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3521). The collections of information in 21 CFR 570.17 and 571.1 have been approved under OMB control number 0910–0546; the collections of information under 21 CFR part 570, subpart E have been approved under OMB control number 0910–0342; and the collections of information under 21 CFR part 58 have been approved under OMB control number 0910–0119. PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 IV. Electronic Access Persons with access to the internet may obtain the draft guidance at either https://www.fda.gov/AnimalVeterinary/ GuidanceComplianceEnforcement/ GuidanceforIndustry/default.htm or https://www.regulations.gov. Dated: February 6, 2020. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2020–02867 Filed 2–12–20; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2020–N–0008] Request for Nominations of Individuals and Industry Organizations for the Patient Engagement Advisory Committee AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is requesting that industry organizations interested in participating in the selection of a pool of nonvoting industry representatives to serve as temporary nonvoting members on the Patient Engagement Advisory Committee (the Committee) in the Center for Devices and Radiological Health notify FDA in writing. FDA is also requesting nominations for temporary nonvoting industry representatives to be included in a pool of individuals to serve on the Committee. Nominees recommended to serve as a temporary nonvoting industry representative may either be selfnominated or nominated by an industry organization. This position may be filled by representatives from different medical device areas based on expertise relevant to the topics being considered by the Committee. Nominations will be accepted for upcoming vacancies effective with this notice. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups. DATES: Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interest must send a letter stating that interest to the FDA by March 16, 2020 (see sections I and II of this document for details). SUMMARY: E:\FR\FM\13FEN1.SGM 13FEN1

Agencies

[Federal Register Volume 85, Number 30 (Thursday, February 13, 2020)]
[Notices]
[Pages 8297-8298]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-02867]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-D-0064]


Pre-Submission Consultation Process for Animal Food Additive 
Petitions or Generally Recognized as Safe Notices; Draft Guidance for 
Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, we, or Agency) is 
announcing the availability of a draft guidance for industry (GFI) #262 
entitled ``Pre-Submission Consultation Process for Animal Food Additive 
Petitions or Generally Recognized as Safe (GRAS) Notices.'' This draft 
guidance document, when finalized, will help industry submit 
information for effective and efficient consultations with FDA 
regarding investigational animal food substances.

DATES: Submit either electronic or written comments on the draft 
guidance by April 13, 2020 to ensure that the Agency considers your 
comment on this draft guidance before it begins work on the final 
version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as 
follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2020-D-0064 for ``Pre-Submission Consultation Process for Animal 
Food Additive Petitions or Generally Recognized as Safe (GRAS) 
Notices.'' Received comments will be placed in the docket and, except 
for those submitted as ``Confidential Submissions,'' publicly viewable 
at https://www.regulations.gov or at the Dockets Management Staff 
between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your

[[Page 8298]]

comments only as a written/paper submission. You should submit two 
copies total. One copy will include the information you claim to be 
confidential with a heading or cover note that states ``THIS DOCUMENT 
CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, 
including the claimed confidential information, in its consideration of 
comments. The second copy, which will have the claimed confidential 
information redacted/blacked out, will be available for public viewing 
and posted on https://www.regulations.gov. Submit both copies to the 
Dockets Management Staff. If you do not wish your name and contact 
information to be made publicly available, you can provide this 
information on the cover sheet and not in the body of your comments and 
you must identify this information as ``confidential.'' Any information 
marked as ``confidential'' will not be disclosed except in accordance 
with 21 CFR 10.20 and other applicable disclosure law. For more 
information about FDA's posting of comments to public dockets, see 80 
FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.
    You may submit comments on any guidance at any time (see 21 CFR 
10.115(g)(5)).
    Submit written requests for single copies of the guidance to the 
Policy and Regulations Staff (HFV-6), Center for Veterinary Medicine, 
Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. 
Send one self-addressed adhesive label to assist that office in 
processing your requests. See the SUPPLEMENTARY INFORMATION section for 
electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Ciro Ruiz-Feria, Center for Veterinary 
Medicine (HFV-229), Food and Drug Administration, 7519 Standish Pl., 
Rockville, MD 20855, 240-402-6282, [email protected].

SUPPLEMENTARY INFORMATION: 

I. Background

    FDA is announcing the availability of a draft GFI #262 entitled 
``Pre-Submission Consultation Process for Animal Food Additive 
Petitions or Generally Recognized as Safe (GRAS) Notices.'' This draft 
guidance document, when finalized, will facilitate pre-submission 
consultation between FDA and industry by providing recommendations for 
submissions to investigational food additive (IFA) files, circumstances 
under which the submission of study protocols is recommended, 
information on FDA's review process for IFA submissions, and best 
practices for communication between FDA and industry regarding these 
submissions or related issues. Such consultations are intended to 
assist industry in complying with applicable requirements if they 
proceed to filing a food additive petition (animal use) or concluding 
that a substance is GRAS for its intended use in animal food.
    Development of this guidance is a requirement of the Animal Drug 
and Animal Generic Drug User Fee Amendments of 2018 (Pub. L. 115-234). 
Draft guidance is required to be issued by February 14, 2020, with 
final guidance issuing not later than 1 year after the close of the 
comment period on the draft guidance.

II. Significance of Guidance

    This level 1 draft guidance is being issued consistent with FDA's 
good guidance practices regulation (21 CFR 10.115). The draft guidance, 
when finalized, will represent the current thinking of FDA on the pre-
submission consultation process for animal food additive petitions or 
GRAS notices for intended use in animal food. It does not establish any 
rights for any person and is not binding on FDA or the public. You can 
use an alternative approach if it satisfies the requirements of the 
applicable statutes and regulations.

III. Paperwork Reduction Act of 1995

    This draft guidance refers to previously approved FDA collections 
of information. These collections of information are subject to review 
by the Office of Management and Budget (OMB) under the Paperwork 
Reduction Act of 1995 (44 U.S.C. 3501-3521). The collections of 
information in 21 CFR 570.17 and 571.1 have been approved under OMB 
control number 0910-0546; the collections of information under 21 CFR 
part 570, subpart E have been approved under OMB control number 0910-
0342; and the collections of information under 21 CFR part 58 have been 
approved under OMB control number 0910-0119.

IV. Electronic Access

    Persons with access to the internet may obtain the draft guidance 
at either https://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm or 
https://www.regulations.gov.

    Dated: February 6, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-02867 Filed 2-12-20; 8:45 am]
 BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.